Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04525222 · ClinicalTrials.gov registry record · Phase 1
mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 242
- Enrollment target
NCT04525222: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT04525222 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 242 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (303% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04525222, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 242 participants
- Enrollment target
Study Summary
This phase I trial investigates a new smartphone application (called Actify) for improving population-level smoking cessation and mood management. Actify delivers behavioral activation therapy for depression as part of a smoking cessation intervention and will be compared to another smoking cessation smartphone application that is based on current clinical practice guidelines. Participants will be randomly assigned to receive one of two smartphone applications and accompanying text notifications to help with quitting smoking and improved mood.
Primary Outcome
Overall treatment satisfaction is reported on a Likert-type scale, with response choices ranging from "not at all=1" to "very much=5". Higher values are associated with higher level of satisfaction.
Interventions
- OTHER Survey Administration
- OTHER Health Promotion and Education
- BEHAVIORAL Smoking Cessation Intervention (Actify app)
- BEHAVIORAL Smoking Cessation Intervention (Current Standard Care app)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2022-05-09 |
| Est. Completion | 2023-04-12 |
| Phase | Phase 1 |
What the finished NCT04525222 record still lists
NCT04525222 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (303% higher).
The record links to 0 conditions, and to 4 interventions - of which Survey Administration is the first listed.
NCT04525222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04525222 about?
NCT04525222 is a clinical study titled "mHealth Mood Management Tool (Actify) to Improve Population-Level Smoking Cessation". This phase I trial investigates a new smartphone application (called Actify) for improving population-level smoking cessation and mood management. Actify delivers behavioral activation therapy for depression as part of a smoking cessation intervention and will be compared to another smoking cessatio...
What is the current status of trial NCT04525222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 242 participants. The study started on 2022-05-09. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT04525222?
The interventions under investigation include: Survey Administration (OTHER), Health Promotion and Education (OTHER), Smoking Cessation Intervention (Actify app) (BEHAVIORAL), Smoking Cessation Intervention (Current Standard Care app) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04525222?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04525222's enrollment target sits among peer trials
242 194th of 2000 higher than 1,805 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI